Obeticholic acid, commercially known as Ocaliva, is a prescription medication developed by Intercept Pharmaceuticals for the treatment of primary biliary cholangitis.
Here are three of the upcoming presentations:
1. “Predicted Risk of End Stage Liver Disease with Continued Standard of Care and Subsequent Addition of Obeticholic Acid in Patients with PBC”
2. “Long-Term Effect of Obeticholic Acid on Transient Elastography and AST to Platelet Ratio Index in Patients with PBC”
3. “Obeticholic acid, a synthetic FXR agonist, prevents hepatic inflammation and fibrosis in a novel mouse model of non-alcoholic steatohepatitis”
There will be a total of 11 presentations on obeticholic acid at the meeting.
More articles on gastroenterology and endoscopy:
Aspirin reduces risk of tumors with low levels of tumor-infiltrating lymphocytes: 3 study insights
AGA, Asociación Mexicana de Gastroenterología to host joint symposium for Mexican Gastroenterology Week: 3 notes
Inflammatory bowel disease 3 times more common than previous estimates: 5 takeaways
